Boston Trust Walden Corp Raises Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Boston Trust Walden Corp increased its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 43.5% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 831,627 shares of the company's stock after purchasing an additional 252,089 shares during the period. Boston Trust Walden Corp owned approximately 1.68% of Prestige Consumer Healthcare worth $64,942,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in the company. DAVENPORT & Co LLC purchased a new position in Prestige Consumer Healthcare in the fourth quarter worth $1,212,000. Caprock Group LLC purchased a new position in shares of Prestige Consumer Healthcare in the 4th quarter valued at about $210,000. Pacer Advisors Inc. increased its holdings in shares of Prestige Consumer Healthcare by 83.0% in the 4th quarter. Pacer Advisors Inc. now owns 3,352 shares of the company's stock valued at $262,000 after purchasing an additional 1,520 shares in the last quarter. KBC Group NV lifted its stake in shares of Prestige Consumer Healthcare by 28.3% in the fourth quarter. KBC Group NV now owns 2,048 shares of the company's stock valued at $160,000 after purchasing an additional 452 shares during the period. Finally, Blue Trust Inc. boosted its holdings in Prestige Consumer Healthcare by 24.8% during the fourth quarter. Blue Trust Inc. now owns 2,190 shares of the company's stock worth $158,000 after buying an additional 435 shares in the last quarter. Institutional investors and hedge funds own 99.95% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Sidoti cut shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 target price for the company. in a report on Monday, December 9th. StockNews.com raised Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Friday, January 24th. DA Davidson reissued a "buy" rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Finally, Raymond James upgraded Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $85.25.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, EVP Adel Mekhail sold 9,063 shares of the firm's stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the sale, the executive vice president now directly owns 18,365 shares of the company's stock, valued at $1,505,930. This trade represents a 33.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the company's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. This trade represents a 3.28 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,810 shares of company stock worth $3,187,300. 1.60% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Trading Up 14.6 %

Shares of PBH traded up $11.11 during midday trading on Thursday, hitting $87.21. The stock had a trading volume of 768,028 shares, compared to its average volume of 306,855. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare Inc. has a fifty-two week low of $60.00 and a fifty-two week high of $87.39. The business has a 50-day simple moving average of $79.13 and a two-hundred day simple moving average of $75.26. The firm has a market cap of $4.31 billion, a P/E ratio of 21.22, a price-to-earnings-growth ratio of 2.15 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating analysts' consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. As a group, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.46 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.